Trellis Bioscience discloses four prior private securities offerings in Form D filings

Trellis Bioscience, Inc., a Delaware corporation based in Redwood City, California, filed four Form D notices with the SEC, each signed by Chief Financial Officer Nora Mende on 2026-10-21. The company is organized as a corporation under Delaware law and has existed for over five years.¹ Nora Mende serves as Chief Financial Officer and Larry Kauvar serves as Chief Science Officer, both listed as related persons at the company's 702 Marshall Street address in Redwood City.¹

The filings cover four separate offerings. The earliest, a Series B Interests offering, had a date of first sale of 2010-04-29², with a total amount sold of $22,892,056² and 88 investors having participated².

A "Series 2022 Bridge" offering, which included convertible notes with 20% warrant coverage³, had a date of first sale of 2022-06-01³ and raised a total amount sold of $985,000³ from 6 investors³.

A "Series 2023 Bridge" offering, also structured as convertible notes with 20% warrant coverage⁴, launched with a date of first sale of 2023-04-20⁴ and sold $1,350,000⁴ to 9 investors⁴.

Most recently, a "Series 2024 Bridge" offering, also including convertible notes with 20% warrant coverage¹, had a date of first sale of 2024-10-04¹ and raised $4,094,500¹ from 27 investors¹.

Each offering relied on the Rule 506(b) exemption^1,4,2,3, and none of the filings reported sales commissions, finders' fees, or payments to executive officers from the proceeds.